The Pharmaceutical Sustainability Imperative: Industry Commitments and Progress
Leading pharmaceutical companies have made ambitious environmental commitments, signalling the industry's recognition of its responsibilities to the planet. AstraZeneca's Ambition Zero Carbon programme [2] aims to achieve zero carbon emissions from operations across the entire value chain by 2045. The company has already achieved carbon-negative operations and is working systematically to eliminate emissions from its supply chain, which would cut down its total carbon footprint by a staggering 90%.
Having made significant investments in renewable energy and sustainable chemistry, GSK's environmental sustainability strategy [3] is targeting net-zero emissions across its value chain by 2045. They are also pledging interim goals which include a switch to 100% renewable electricity by 2030 and a 50% reduction in Scope 1 and 2 emissions by the same year. Meanwhile, Novartis has committed [4] to reach net-zero greenhouse gas emissions across its value chain by 2040, with science-based targets validated by the Science Based Targets initiative (SBTi). The company's approach encompasses renewable energy adoption, sustainable sourcing, green chemistry, and collaboration with suppliers to reduce emissions throughout the pharmaceutical supply chain.
These commitments reflect growing recognition of the importance of pharmaceutical sustainability. Investors increasingly incorporate environmental, social, and governance (ESG) criteria into their decisions, and regulators are introducing environmental requirements into pharmaceutical oversight as standard. With healthcare systems are prioritising sustainable procurement and patients and professionals alike demanding environmentally responsible medicines, the companies that fail to address sustainability are at significant risk of losing market access, investment capital and stakeholder trust.
Solutions in Sustainable Pharmaceutical Packaging
Pharmaceutical packaging presents substantial opportunities for sustainability innovation, while also facing significant challenges. While traditional packaging prioritised protection and regulatory compliance, this often resulted in multi-material constructions that were unsuitable for recycling. Furthermore, excessive packaging often generates unnecessary waste, while fossil fuel-derived plastics contribute significantly to carbon emissions and environmental pollution.
Mono-material packaging represents one of the most promising sustainability innovations. Traditional blister packs combine aluminium, PVC or PVdC, and adhesives in constructions that cannot be separated for recycling. Advanced mono-material designs maintain barrier properties and product protection whilst enabling recycling through standard waste streams, which can reduce packaging's carbon footprint by 30-50% compared to traditional multi-material alternatives.
Bio-based materials offer another pathway to sustainability, through the use of polymers derived from renewable feedstocks rather than fossil fuels. These materials reduce carbon emissions by 40-60% compared to conventional plastics, while maintaining the same performance as their less sustainable counterparts. The company's life cycle assessments demonstrate substantial environmental benefits across production, use, and end-of-life phases.
The Packaging & Drug Delivery zone at CPHI Milan provides pharmaceutical manufacturers with direct access to these innovations, enabling hands-on evaluation of sustainable materials, discussions with packaging engineers about implementation strategies, and connections with suppliers who can support sustainability transitions. For companies committed to reducing their environmental footprint, the zone offers concentrated access to the solutions that make sustainability goals achievable.
Green Pharma Manufacturing: Process Innovation for Carbon Reduction
Manufacturing operations represent the pharmaceutical industry's most significant direct environmental impact, with energy-intensive processes, substantial water consumption, and chemical waste generation creating environmental challenges that demand innovative solutions. Green pharma manufacturing approaches address these challenges through process optimisation, renewable energy adoption, and circular economy principles.
According to the International Society for Pharmaceutical Engineering's (ISPE) sustainable manufacturing guidance, [5] pharmaceutical manufacturing sustainability encompasses making improvements to energy efficiency, water conservation and recycling, waste minimisation and valorisation, sustainable chemistry principles, and renewable energy integration. Leading manufacturers are implementing these approaches systematically, achieving substantial environmental improvements whilst often reducing operational costs.
Continuous manufacturing represents a transformative approach that delivers both operational and environmental benefits, reducing energy consumption by 30-50% compared to batch processing. This also minimises waste generation through improved process control, decrease water usage through integrated processing, and enables smaller facility footprints that reduce construction materials and ongoing resource consumption.
Green chemistry principles offer another powerful tool for sustainable manufacturing. The American Chemical Society's Green Chemistry Institute Pharmaceutical Roundtable [6] brings together major pharmaceutical companies to develop and share sustainable chemistry approaches. Their findings show a 50-80% reduction in solvent usage, as well as eliminating hazardous reagents and catalysts, improved reaction yields to minimise waste and simplified purification processes to reduce energy and material consumption.
